Wall Street Investors Pivot to Baldness Drug Market Amid GLP-1 Fatigue

Pattern hair loss affects an estimated 80 million Americans, yet no new drugs have been approved since the late 1990s, prompting investors to target the untreated therapeutic market.

31 Aug, 03:09 — 31 Aug, 03:09

Post Share

Sources

Showing 1 of 1 sources

japan-timesMostly Factual22h ago

Forget GLP-1 stocks, baldness drugs are Wall Street’s next goldmine

Pattern hair loss affects an estimated 50 million men and 30 million women in the U.S., but there have been no new approved drugs since the late 1990s.

Read full article →

Wall Street Investors Pivot to Baldness Drug Market Amid GLP-1 Fatigue

Sources

Forget GLP-1 stocks, baldness drugs are Wall Street’s next goldmine

Related Stories

South Korea Reports Record Export Surge in August Driven by Chip Demand

Anthropic Secures $35 Billion Cloud Computing Deal With Nvidia-Backed Lambda

Nigeria Reports 4.43 Percent Economic Growth in Second Quarter

Hyundai Motor South Korean Union Approves New Wage Deal